Recently, we described a heterologous prime-boost strategy using plasmid DNA followed by replicationdefective human recombinant adenovirus type 5 as a powerful strategy to elicit long-lived CD8 ؉ T-cellmediated protective immunity against experimental systemic infection of mice with a human intracellular protozoan parasite, Trypanosoma cruzi. In the present study, we further characterized the protective long-lived Genetic vaccination using the strategy known as the heterologous prime-boost regimen is being pursued as an alternative type of vaccine. This strategy consists of the use of two different vectors, both carrying a gene that encodes the same antigenic protein, for priming and boosting immunizations. This strategy can be particularly important in the case of intracellular pathogens and neoplastic cells, where the effectiveness of the vaccine relies heavily on its capacity to elicit specific immune responses mediated by cytotoxic CD8 ϩ T cells (reviewed in references 22, 31, 38, 39, and 57).